Study of Oral Fampridine-SR in Multiple Sclerosis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2008
To assess the safety and efficacy of 10 milligram (mg) twice a day (b.i.d.) Fampridine-SR in patients diagnosed with multiple sclerosis (MS), in a double-blind, placebo-controlled, parallel group study.
Epistemonikos ID: 6b5a5f59a6c04e1c9053a5909d6b853668d58df1
First added on: Mar 31, 2022